Correlation of Clinical and Laboratory Aspirin Resistance: A Pilot Study
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
Collaborative review of randomized trials of antiplatelet therapy-1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialist collaboration. BMJ 1994; 308: 81–106.
Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 2003; 41: 966–968
Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991; 63: 587-93.
Helgason CM, Tortorice KL, Winckler SR, Penney DW, Schuler JJ, Mc Clelland TJ, et al. Aspirin response and failure in cerebral infarction. Stroke 1993; 24: 345-50.
Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year followup of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
Hegalson CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-6.
Gum PA, Kottke-Marchand K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
Fateh –Moghadam U, Plöckinger N.Cabeza, P. Htun, T. Reuter, S. Ersel, M. Gawaz, R. Dietz, W. Bocksch. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005 42:99–103
Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients, results of the primary prevention project (PPP) trial. Diabetes Care 26:3264–3272.
de Gaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost. 2003; 1:2048-2050.
Sadiq PA, Puri A, Dixit M, Ghatak A, Dwivedi SK, Narain VS, Saran RK, Puri VK. Profile and prevalence of aspirin resistance in Indian patients with coronary artery disease. Indian Heart J. 2005 Nov-Dec; 57(6):658-61.
Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin nonresponder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250:63–66.
Mueller MR, Salat A, Stangl P, et al. Variable platelet response to lowdose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78:1003–1007.
Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-6.
Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003; 326: 82-3.
Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ. 2000; 321(7252):13-7.
Colwell JA, Nesto RW The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003 26: 2181–2188
- There are currently no refbacks.